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Abstract 
This review discusses some approaches developed by the Turin University Pharmaceutical 
Technology group to enhance the entrapment efficiency of mainly hydrophilic molecules within 
nanoparticulate systems, and to optimize their delivery. Many attempts have been made to increase, 
either passively or actively, the delivery of hydrophilic drugs. One approach consists of their 
association to liposomes, in some cases by developing lipophilic prodrugs of anticancer hydrophilic 
molecules, and encapsulating them in liposomes; in some cases these are then further conjugated 
with suitable vectors, to increase targeting efficiency. The transformation of hydrophilic drugs into 
lipophilic prodrugs can also overcome problems of poor entrapment efficiency, and the frequently-
observed rapid release from polymer nanocarriers, for example nanospheres or nanocapsules 
obtained from various PEGylated poly(alkylcyanoacrylate) copolymers. Strategies have also been 
developed to enhance hydrophilic drug entrapment in solid lipid nanoparticles (SLN). Of these, 
hydrophobic ion pairing (HIP) was designed to enable various antitumor drugs to be entrapped in 
SLN produced by the coacervation method. The w/o/w emulsion solvent dilution technique may also 
be employed to entrap peptide drugs, such as insulin, directly in the inner aqueous phase. Another 
strategy entails covalent linkage of antitumoral and antiviral drugs to a squalenoyl-derived chain; this 
produces bioconjugates that spontaneously self-assemble in an aqueous medium as stable 
nanoparticles. Another development comprises mesoporous silica nanoparticles with immobilized 
hydrophilic antioxidants, for topical applications. Ordered mesoporous silica (MCM-41) 
nanoparticles were complexed with hydrophilic antioxidants (Trolox® or rutin) employing different 
inclusion procedures, varying solvent and pretreatment of the silica matrix; on exposure to UV 
illumination, mesoporous silica significantly improved stability over time. Finally, polymer-shelled 
and perfluoropentane-cored nanobubbles have been designed as versatile multifunctional carriers for 
the delivery of gases, drugs and genes; the size range is below 500 nm, with shell thickness in the 30-
50 nm range. 
 
Introduction 
This review presents the expertise of the Pharmaceutical Technology Group of Turin University 
(Italy). Over several years the Group has developed strategies for delivering hydrophilic molecules 
employed in the anticancer field. In the 1980s, two Pharmaceutical Technology research groups 
began exploring new routes in the field of delivering and targeting anticancer agents. One team, 
coordinated by Prof. M.R. Gasco, began by studying and characterizing lipophilic ion-pairs of 
several amine drugs. The research aimed to develop microemulsions for use as drug delivery systems 
(DDS): the novelty of this approach lay in the use of biocompatible surfactants as phospholipids. 
These microemulsions were proposed for the administration of hydrophilic and lipophilic drugs. 
M.R. Gasco patented a novel technique to produce solid lipid nanoparticles by preparing a hot 
microemulsion and dispersing it in cool water.  
The other research team, coordinated by Prof. L. Cattel, took a medicinal chemistry approach. They 




(lectins), or macromolecular conjugates to tumor tissues. Further, collaboration with several 
European research groups lead to the development of particulate delivery systems (liposomes, 
polymer nanoparticles) and, more recently, to the squalenoylation platform.  
Colloidal systems, such as liposomes, nanoparticles, and microemulsions, have mainly been reported 
in the literature for use as carriers of hydrophobic drugs. Delivery of hydrophilic molecules is a 
challenging goal, which requires multidisciplinary approaches. This review essentially focused on 
the various strategies that may be employed to deliver hydrophilic active substances. 
Many drugs are hydrophilic, and many of these are low-molecular weight molecules (less than 500 
Da). According to the United States Pharmacopeia (USP), hydrophilic drugs are classified in the 
range very soluble to soluble in an aqueous medium, if their solubility is higher than 33 mg/ml. 
Hydrophilic drugs are often subject to low intracellular absorption, enzymatic degradation, rapid 
clearance, suboptimal distribution, development of resistance, poor pharmacokinetics, low 
therapeutic index and, in the case of antitumoral drugs, lack of accumulation and retention within the 
tumor. Drug entrapment in colloidal delivery systems can in may cases overcome these difficulties, 
since it may improve pharmacokinetics, protect the drug against in vivo degradation, sustain drug 
release, increase patient comfort by avoiding repetitive injections, and reduce side effects. In the 
treatment of cancer, nanoparticulate systems also possess the advantage of enhancing permeability 
and retention (the EPR effect), resulting in their higher accumulation in tumors [1,2]. The possibility 
of modifying the surface of nanoparticulate systems, for example by PEGylation, leads to stealth 
colloidal systems, which can escape rapid uptake by the mononuclear phagocyte system; the addition 
of specific ligands onto their surface can also provide more effective release at the target site. 
This review will briefly examine the different approaches developed by our group, pointing out the 
originality of our contribution and the most relevant preclinical results obtained thus far. Some of the 
new technologies developed for the delivery of hydrophilic drugs are also applicable also to some 
very low water soluble molecules, which will thus also be mentioned in brief. 
 
1) Liposomes 
Liposomes are nanoconstructs, usually sized at the nanoscale, and consist of natural or synthetic 
phospholipids surrounding a water core. Since phospholipids are the major component of liposomes, 
they are little toxic, biodegradable, and biocompatible. Liposomes form spontaneously when 
phospholipids are dispersed in water. Liposomes composed of natural phospholipids are biologically 
inert and weakly immunogenic, and possess low intrinsic toxicity. Depending on the number of 
layers and the diameter, liposomes are classified as multilamellar vesicles (MLVs, diameter >200 
nm), large unilamellar vesicles (LUVs, diameter 100–400 nm), and small unilamellar vesicles 
(SUVs, diameter <100 nm). By surface charge (zeta potential) they are classified as cationic, neutral, 
or anionic liposomes. 
Thanks to their favorable characteristics, liposomes have been widely used as carriers for different 
kinds of drugs. In particular, different approaches and preparation methods have been reported for 
the encapsulation of either hydrophilic or hydrophobic antitumoral drugs [3]. 
A number of different anticancer drugs with different physico-chemical features have been 
encapsulated in liposomes by Turin University Group, with the goals of improving their cytotoxic 
activity, extending their plasma half-life, and reducing their side effects. The encapsulation of low-
molecular-weight water-soluble drugs is, in most cases, characterised by poor trapping efficiency and 
rapid leakage in vivo [4], limiting both shelf life and clinical utility of these liposomes. To overcome 
these problems, lipophilic prodrugs of hydrophilic drugs were developed and encapsulated in 
liposomes. This approach was initially used to prepare liposomes and immunoliposomes containing 
5-fluorouridine (5-FUR) lipophilic prodrugs [5]. The parent drug, 5-FUR, and the prodrugs 5’-
succinyl-5-FUR and 5’-palmitoyl-5-FUR were encapsulated in liposomes, and encapsulation 
efficiency, drug leakage, stability, and size were evaluated. The results showed that 5’-palmitoyl-5-




encapsulation efficiency. Moreover, differential scanning calorimetry (DSC) analysis showed that 
the compound strongly interacted with the liposomal bilayer. To increase the drug delivery 
efficiency, these liposomes were then further conjugated with an AR-3 monoclonal antibody, 
targeted to human colon carcinoma. The immunoliposomes were prepared from phospholipidic 
vesicles incorporating a maleimido reactive derivative of phosphatidylethanolamine, able to react 
with the thiolated monoclonal antibody, as shown in Figure 1. The in vitro antitumor activity of 
liposomes and immunoliposomes was determined on the HT-29 human colon carcinoma cell line; 
the results showed that the targeted liposomes were more cytotoxic than their conventional 
counterparts. Both plain and targeted liposomes were then i.p. injected into athymic mice grafted 
with the HT-29 cell line; also in this case, the immunoliposomes were more effective than the plain 
variety as antitumor agents. Only 5% of residual tumor mass was present at the end of the therapy in 
mice treated with the immunoliposomes. 
Gemcitabine (GEM) is an anticancer drug, indicated for pancreatic cancer, that is rapidly deaminated 
to an inactive metabolite; it must therefore be administered at a very high dose. A series of prodrugs 
of GEM was synthesized with the aim of improving its metabolic stability and facilitating its 
encapsulation in liposomes [6]. The GEM 4-amino group was derivatized with C5, C12 and C18 
linear-chain acyl derivatives (Figure 2). Stability of the prodrugs at storage, in buffers, in plasma, 
and with the lysosomal intracellular enzyme catepsins was evaluated. The results in buffers 
confirmed the high stability of the amide bond. Also in plasma, the prodrugs showed high stability 
and marked resistance to deamination. They were incubated with cathepsin B and D to evaluate the 
selective hydrolysis of the amide bond inside the cell by liposomal enzymes. After 24 h, 60% of the 
prodrug had undergone hydrolysis of the amide bond, without degradation of free GEM occurring. 
The characteristics of liposomes containing these prodrugs were also studied, and it emerged that 
GEM lipophilic derivatives containing C12 and C18 acyl chains showed the best results, in terms of 
incorporation into liposomes, and the corresponding drug-loaded carriers showed higher cytotoxic 
activity than the free drug, against both HT-29 colon and KB nasopharyngeal human carcinoma cell 
lines [6]. The pharmacokinetic behavior and the in vivo antitumor activity of the parent drug, and of 
the gemcitabine prodrug alone and encapsulated in liposomes, were evaluated. Liposomes containing 
the prodrug showed both longer plasma half life and greater tumor regression than either control or 
gemcitabine [7]. 
The GEM lipophilic prodrugs were studied in interaction with biomembranes through DSC, in order 
to evaluate the effect of the length of the acyl chain on the ability to interact with a model 
biomembrane in an aqueous compartment: the goal was to obtain biomimetic information on the 
prodrugs’ lipophilic character and solubility [8]. As synthetic biomembrane models, liposomal MLV 
and LUV were used; these were composed of dimyristoylphosphatidylcholine (DMPC) and of 
distearoylphosphatidylcholine (DSPC). These studies involved the addition of GEM lipophilic 
prodrugs to the biomembrane models, the transfer of these compounds through an aqueous medium, 
and the migration to empty liposomes from liposomes containing a known quantity of GEM or of its 
4-(N)-acyl derivatives. The results showed that the free drug alone does not interact with the 
biomembrane models used; conversely, the 4-(N)-acylgemcitabine derivatives interacted with the 
biomembrane models, this interaction being dependent on the acyl chain length of the phospholipids 
in the model biomembranes, and on the acyl chain length of the prodrugs.  
The lipophilic GEM prodrugs were also studied to determine their interaction with biomembrane 
models, through the Langmuir-Blodgett (LB) technique [9]; this is one of the commonest ways to 
study the interaction between drugs and phospholipids. Monolayers are an excellent model to study 
two-dimensional ordering, with two thermodynamical variables, temperature and pressure, being 
readily controlled. Conclusions about the mixing process of two pure monolayers can be drawn by 
comparing surface pressure-area isotherms of mixed and pure films. Results provide indications on 




interactions enable hypotheses to be formulated concerning the intake and collocation of the 
compounds within the membrane. 
The interfacial behaviour of monolayers comprising DMPC, plus GEM or lipophilic prodrugs at 
increasing molar fractions, was studied at the air/water interface at temperatures below (10 °C) and 
above (37 °C) the lipid phase transition. The results show that the compounds interact with DMPC, 
producing mixed monolayers that are subject to an expansion effect, depending on the prodrug chain 
length. A comparison of the results shows that GEM-derivatives in mixed monolayers substantially 
exert an expansion effect, which is particularly strong in the case of GEM-C12. GEM-C5, although it 
possesses a much shorter hydrophobic tail than C-18, exerts a similar effect: GEM-C18, possessing a 
longer chain than DMPC, interacts with the phospholipid chains; the slight expansion effect might be 
due to the long chain tilting. 
Liposomes containing the C12 acyl chain of GEM were further modified with a vector, to increase 
their targeting ability. Hyaluronic acid (HA) was chosen as vector, since its principal surface 
receptor, CD44, is overexpressed on a variety of tumors [10,11]. Moreover, HA is biodegradable, 
biocompatible, and can be chemically modified. Initially, conjugates between a phospholipid and HA 
of two different molecular weights (4800 and 12000 Da) were synthesized; they were purified and 
characterized, and then introduced into liposomes during preparation. Different liposomal 
formulations were prepared and their physico-chemical characteristics were evaluated. In vitro 
biological studies, including confocal microscopy, showed that HA facilitates recognition of 
liposomes by CD44+ cells, and that the uptake increased as the HA molecular weight increased. It 
was also observed that the cytotoxicity was higher in HA-liposomes than in plain liposomes [12]. 
The in vivo antitumoral activity of the liposomal formulations was further analysed in a mouse 
xenograft tumor model of human pancreatic adenocarcinoma, showing that liposomes obtained using 
high molecular weight HA were the most efficient. 
 
2) Solid lipid nanoparticles (SLN) 
Nanoparticles are making steady progress as drug carriers, because of their size-dependent 
properties. Owing to the biocompatibility and versatility of the lipid component, lipid nanoparticles 
have many advantages over polymer nanoparticles, and have been widely used for active drug 
delivery [13]. Solid lipid nanoparticles (SLN) are composed of a solid lipid matrix, for example 
glycerides, fatty acids or waxes, and are stabilized by physiologically-compatible emulsifiers, such 
as phospholipids, bile salts, polysorbates, polyoxyethylene ethers or polyvinyl alcohols. The lipids 
used for their production are solid at room temperature, and most of them have low toxicity, giving 
them approved status, for example GRAS (Generally Recognized as Safe). SLN are colloidal 
systems with approximate mean diameter between 50 and 1000 nm. They are produced with 
different methods [14]: in many cases these start from emulsions, such as the hot homogenization 
method [13], or from microemulsions [15], such as the microemulsion dilution method. These 
methods require high operating temperatures, which may be unsuitable for encapsulating 
thermosensitive drugs. SLN can also be produced by solvent-based methods (solvent injection [16], 
solvent evaporation method [17], solvent diffusion method [18]); one of the main advantages of 
these methods is the mild operating temperature, which can be useful for encapsulating 
thermosensitive drugs; however, toxicological issues concerning the solvent used are a limiting 
aspect.  
The fatty acids coacervation method was recently developed to prepare SLN (Figure 3); this 
production method starts from alkaline salts of fatty acids, and enables drugs, including 
thermosensitive drugs, to be incorporated without using very complex equipment or dangerous 
solvents [19]. This method is based on a slow interaction between a micellar solution of a sodium 
salt of a fatty acid and an acid solution (coacervating solution) in the presence of an appropriate 




Drugs can be encapsulated in SLN in different ways, depending on the preparation method 
employed. However, in all preparation techniques, an interaction occurs between drug and lipid, 
which leads to the entrapment phenomenon. Drugs can be distributed in the lipid matrix in different 
ways: in a homogeneous matrix (the drug is molecularly dispersed or is present in amorphous 
clusters in the lipid matrix), in the nanoparticle shell (the drug is mainly in the outer shell that covers 
a lipid core) or as a lipid-coated core (the drug starts to precipitate before the lipid, and the lipid shell 
forms around this core). 
Briefly, drugs can be divided into hydrophilic and hydrophobic, by their water solubility and 
partition coefficient. During SLN preparation, different strategies must be adopted to reduce 
partitioning of the drug into the outer water phase, and to enhance drug entrapment [21]. The most 
important ways of loading hydrophilic drugs into SLN are: 
1. starting from a template that allows encapsulation of hydrophilic drugs: i.e. w/o/w emulsion with 
an organic solvent [17,18] or w/o/w microemulsion [22] or o/w emulsion with partially water 
miscible organic solvents [23]; 
2. using the hydrophobic ion pairing (HIP) technique: this is possible between certain charged 
hydrophilic drugs and opposite-charged surfactants. It decreases the drug’s water solubility and 
increases the drug’s apparent partition coefficient, enhancing drug encapsulation within the 
nanoparticles [24,25]; 
3. using polymer lipid hybrid nanoparticles: a complex between drug and ionic polymer is formed 
by neutralizing the charges of the drug with a polymer counterion, and the formed complex is 
entrapped into nanoparticles [26,27]; 
4. preparing lipid-drug conjugate nanoparticles [28]; 
5. using water free preparation methods [29]; 
6. using lipophilic prodrugs of the hydrophilic drug [30,31]. 
Insulin-loaded glyceryl monostearate nanoparticles have been prepared by the Turin University 
Group starting from w/o/w by simple water dilution [32]. SLN of spherical shape, with mean 
diameter in the 600–1200 nm range, and with up to 40% insulin entrapment efficiency (EE%) were 
obtained. Through preliminary solvent screening, the stability of the entrapped insulin was 
maintained, as was its biological activity after administration in vivo. 
The HIP technique has been widely applied. Doxorubicin (DOX) was entrapped within behenic acid 
SLN, prepared by the coacervation method, by employing HIP with sodium dioctylsulfosuccinate 
(AOT), a negatively-charged surfactant used as counter-ion [33]. DOX is one of the leading 
anticancer drugs in clinical oncology, with a broad spectrum of activity against various solid and 
hematologic neoplastic diseases; it is commonly employed in numerous anticancer therapeutic 
regimens. DOX-SLN characterization indicated that DOX-AOT was loaded into SLN with good 
EE%, and that SLN-entrapped DOX maintained its cytotoxic activity against glioma cell lines; 
moreover, its permeation through hCMEC/D3 cell monolayer, taken as model of the blood-brain 
barrier, was increased when the drug was entrapped in SLN. 
Stearic acid SLN loaded with different peptides were prepared using the coacervation method [25]. 
Leuprolide acetate and insulin were loaded into SLN, using AOT and sodium dodecylsulphate (SDS) 
respectively as counter ions. All peptide-loaded SLN had diameter in the 320-520 nm range; insulin 
EE% was about 90%, and leuprolide EE% depended on ion pair stoichiometry (from 48% to 86%). 
The mild heating necessary for the coacervation process did not affect the chemical stability of the 
peptides. The same team [24] also prepared stearic acid cisplatin-loaded SLN. Cisplatin, a 
hydrophilic anti-tumor agent, could be loaded thanks to the formation of a hydrophobic ion-pair with 
AOT. Particle size was in the 275-525 nm range; cisplatin EE% was up to 90%, depending on both 
stearic acid concentration and stabilizer type and concentration. In vitro cisplatin release showed a 
burst effect of about 10-20%, corresponding to the non-entrapped drug, and then complete drug 
release was reached after 24 h. The HIP technique was also used to prepare methotrexate (MTX)-




dichloride (DEQ), a cationic surfactant currently used as antimicrobial agent, markedly increased 
drug EE% within SLN. MTX-DEQ-loaded SLN also showed increased cytotoxicity against breast 
cancer cell lines compared with drug solution, while blank SLN showed good biocompatibility. 
Increased MTX plasmatic concentration and increased accumulation within breast neoplastic tissue 
were achieved when MTX was loaded into SLN as an ion pair, compared with drug solution. 
Higher molecular weight drugs have also been entrapped in SLN, including bevacizumab (BVZ) 
[35]. BVZ is a recombinant humanized monoclonal antibody that inhibits angiogenesis by inhibiting 
vascular endothelial growth factor A (VEGF-A). It is used to treat various cancers, including 
colorectal, lung, breast, glioblastoma, kidney and ovarian. BVZ was entrapped in stearic acid SLN as 
AOT-BVZ ion pair with 30% EE%. When entrapped in SLN, BVZ increased its in vitro activity as 
VEGF-A inhibitor and increased by up to 70%,its in vitro capacity to permeate through the 
hCMEC/D3 cell monolayer, taken as model of the blood-brain barrier, compared to BVZ solution. 
HIP have also been used to enhance the loading of highly water-soluble drugs [26,27], in studies that 
loaded cationic hydrophilic anticancer drugs, such as DOX-HCl, verapamil and quinidine, following 
the formation of ionic complex with various anionic polymers, such as dextran sulphate, sodium 
alginate, sodium stearate. The team prepared SLN by the microemulsion dilution technique, and 
obtained mean diameters in the 180-300 nm range, depending on the type and content of both drug 
and polymer. Ionic complexation with dextran sulphate generally improved (two- to fourfold) 
loading of the three cationic drugs tested. 
The lipid drug conjugates preparation strategy has been used to incorporate hydrophilic drugs into 
SLN [28]. The antitrypanosomal drug diminazene, used as model drug, reacts with fatty acids to 
form water-insoluble salts, for example diminazene distearate and dioleate; these salts were 
transformed into nanoparticles using the high-pressure homogenization technique. Nanoparticle size 
was in the 360-440 nm range, and high drug loading (33%, w/w) was obtained for the highly-water-
soluble drug diminazene diaceturate. 
Another strategy that can be utilised to load hydrophilic drugs into SLN is the free water preparation 
method. Insulin-loaded SLN may be prepared by the electrospray technique [29]. An electric field is 
applied to a lipid-drug solution in a syringe connected to a pump. The applied high-voltage electric 
field forces the polymer solution out of the syringe in jet form; along the jet’s trajectory, the solvent 
gradually evaporates and the particles are deposited on the collecting plate. The apparatus is 
contained in a closed transparent case, at 20 or 40 °C. The great advantage offered by electrospraying 
over other commonly-used methods is that it is a one-step process. Insulin was entrapped into the 
particles with high encapsulation efficiency, by formation of an ion-pair with SDS. Far-ultraviolet 
circular dichroism spectroscopy indicated that electrospraying did not modify the secondary structure 
of insulin. In vitro prolonged release over 24 hours was observed after an initial burst effect. 
3’-5’-dioctanoyl-5-fluoro-2’-deoxyuridine (DO-FUdR, a lipophilic derivative of the hydrophilic drug 
5-fluoro-2’-deoxyuridine, FUdR), has been entrapped in SLN using a thin-layer ultrasonication 
technique [30]. The mean particle size of DO-FUdR SLN was 76 nm and EE% was 96.6%. It was 
found that SLN improved the ability of the drug to penetrate through the blood–brain barrier: after 
intravenous administration of DO-FUdR SLN, the brain concentration of FUdR was more of 10 fold 
that achieved with plain FUdR.  
In another study [31] lipophilic prodrugs were used to entrap hydrophilic molecules in SLN. A 
myristic ester of RU 58841, a potent hydrophilic nonsteroidal antiandrogen used in the treatment of 
acne and androgenetic alopecia, was synthesised to improve entrapment of the drug in SLN. It was 
found that the lipophilicity of the drug and that of the carrier improved drug uptake by the hair 
follicles, and that SLN can act as a slow release system, even achieving low systemic drug levels.  
In conclusion, SLN may be considered promising DDS, owing to their biocompatibility and 






3) Polymer nanoparticles 
Thanks to the wide range of polymers and nanoparticle preparation methods, hydrophilic molecules 
can also be encapsulated in polymer-based nanoparticles, both nanospheres and nanocapsules. 
Nanospheres are matrix systems in which the drug is dispersed within the polymer, throughout the 
particle. Nanocapsules are vesicular systems in which the drug is located in an inner cavity 
surrounded by a thin polymer layer. 
To overcome the poor entrapment efficiency of hydrophilic drugs in polymer nanocarriers, and the 
frequently observed rapid release, several strategies have been developed [36]. Generally, 
hydrophilic molecules can be loaded onto polymer nanospheres, either by entrapping the drug within 
the polymer matrix (by adding the drug during nanoparticle formation) or by adsorption onto 
preformed nanocarriers. If the drug is encapsulated during the nanoparticle fabrication process, 
several parameters are involved. As an example, in the emulsion polymerization of 
alkylcyanoacrylate monomers, the monomer type, pH, and drug concentration play crucial roles in 
the polymerization rate, which, for instance, is faster for monomers with shorter chain lengths, 
facilitating mechanical trapping of the drug [37]. When nanospheres are prepared from a preformed 
polymer by nanoprecipitation, generally low entrapment efficiency levels are obtained, because of 
the hydrophobic nature of polymers, for instance, occurs with polyesters [38]. Nevertheless, it is 
possible to increase the loading of an ionizable drug during the nanoprecipitation process by 
adjusting the pH of the outer media [39]; this modification affects the ionization of the drug and, 
hence, the solubility: an ionic substance tends to stay in the water phase, while the molecular form is 
more likely to be attached to the hydrophobic polymer phase and more efficiently encapsulated. 
In the light of these findings, the Turin University Group prepared DOX-loaded polymer 
nanospheres and nanocapsules via solvent displacement in confined impinging jets reactors (CIJR) 
[40,41]. CIJR are small passive mixers in which very fast turbulent mixing of the solvent (i.e., 
acetone) and of the antisolvent (i.e., water) solutions occurs under controlled conditions. These 
devices can be operated continuously, and can easily be scaled up. Two different types of DOX were 
considered: the commercially-available DOX hydrochloride (DOX-HCl), which has minimal 
solubility in organic solvents, and DOX free base (DOX-FB), which, conversely, is soluble in 
organic solvents but has very low solubility in water [41]. A PEGylated amphiphilic biodegradable 
copolymer, poly(methoxypolyethyleneglycol cyanoacrylate-co-hexadecyl cyanoacrylate) 
(poly(MePEGCA-co-HDCA)), was used to prepare DOX-loaded nanoparticles, and the effect of the 
operating parameters was investigated. For the nanoprecipitation process, DOX-FB was dissolved in 
the organic solvent (acetone or tetrahydrofuran), while DOX-HCl was added to the water phase. The 
results showed that DOX-FB-loaded nanoparticles were smaller than DOX-HCl-loaded 
nanoparticles, and the zeta potential was less sensitive to operating conditions. These results 
suggested that DOX-FB molecules could be properly incorporated inside the polymeric matrix, 
whereas DOX-HCl could only be partially incorporated inside the particles, with a fraction 
interacting with the surface and altering its properties [41]. 
Other preparation methods afford greater drug loading into polymer nanoparticles, such as the double 
w/o/w emulsion technique [42] and the use of reverse micelles-containing polylactic acid (PLA) 
nanoparticles [43]. Moreover, the addition of a polyanion can be a useful strategy to compensate a 
polymer positive charge, such as that of chitosan, a naturally positively-charged polymer. Although 
chitosan nanoparticles are able to imbibe large quantities of water, thus facilitating the encapsulation 
of hydrophilic molecules, the positive charge limits cationic drug encapsulation. The addition of a 
negatively-charged molecule, such as polyaspartic acid, can promote drug entrapment [44]. 
Conversely, negatively-charged nucleic acids are efficiently loaded in pure chitosan nanoparticles 
[45]. Alginate, a natural water-soluble polymer, also forms hydrogel nanoparticles suitable for the 
encapsulation of hydrophilic compounds [46]. 
To efficiently adsorb a drug onto the polymer nanoparticle surface, the physico-chemical 




interaction between drug and nanoparticle surface [37]. The association may arise from ionic 
interactions between the polymer and a charged drug [47]. Moreover, drug absorption is dependent 
on the concentration of the drug in the incubation medium [48] and can be increased by modifying 
the nanoparticle surface [49]. 
Another strategy to entrap hydrophilic compounds in nanocarriers consists of preparing polymer 
nanocapsules with an aqueous inner core. In these carriers, the hydrophilic drug is directly 
solubilized in the internal water. The aqueous-core nanocapsules are generally produced by a two-
step method consisting first of generating aqueous droplets in a continuous organic phase, then 
reinforcing the polymeric interface (for a review see [36]). The advantages of aqueous-core 
nanocapsules are high drug encapsulation efficiency and low polymer content compared to polymer 
nanospheres. 
To make possible their encapsulation in the lipophilic matrix of nanoparticles, hydrophilic drugs can 
also be modified chemically, by transforming them into prodrugs with higher lipophilicity. This 
approach requires a linkage strategy that modifies the drug without causing a loss of activity. The 
Turin group encapsulated GEM and a series of its lipophilic prodrugs into nanospheres and oily-core 
nanocapsules (Figure 2) [50]. The nanoparticles were prepared by nanoprecipitation of an 
amphiphilic biodegradable PEGylated poly(alkylcyanoacrylate) copolymer, the 
poly(aminopolyethyleneglycol cyanoacrylate-co-hexadecyl cyanoacrylate) (poly(H2NPEGCA-co-
HDCA)) [51]. GEM normally suffers from rapid plasmatic metabolization. Its transformation into 
lipophilic derivatives (in which an acyl chain of increasing length is covalently coupled to its 4-
amino group), together with encapsulation in nanospheres or nanocapsules, protected GEM both 
chemically and physically. The results showed that the increased lipophilicity enabled GEM to be 
efficiently encapsulated in poly(H2NPEGCA-co-HDCA) nanocarriers, while the hydrophilic parent 
drug was not entrapped. Moreover, GEM lipophilic derivatives were found to release the free drug 
once inside the cell. 
 
4) Squalene-derived nanoparticles 
In 2004, some researchers of the Turin University team, together with Prof P. Couvreur’s group 
(University of Paris-Sud, France), discovered that the covalent linkage of various hydrophilic 
nucleoside drugs, such as GEM, affords bioconjugates that spontaneously self-assemble in an 
aqueous medium to form stable nanoparticles, having diameters in the 100-200 nm range [52,53]. 
This strategy can be exploited to give impressively high drug loading, together with high therapeutic 
efficiency and, in most cases, the possibility to overcome tumour’s resistance to currently-available 
treatments and/or to reduce the drug’s side effects. This therefore opens the way to a new and 
original approach for delivering therapeutic compounds. In particular, the first squalenoyl derivative, 
4-(N)-squalenoyl-gemcitabine (Sq-GEM), administered by the intravenous route, has been shown to 
improve the drug therapeutic index, at the same time increasing its in vitro toxicity against tumor 
cells about six-fold, while decreasing its toxicity against healthy cells [54]. The Sq-GEM 
nanoassemblies also possessed much stronger antitumoral activity than free GEM when administered 
by the oral route to rats in which leukaemia had been induced by RNK-16 LGL cells [55]. The 
possibility of administration by several routes, the resistance to deamination, the increased 
bioavailability, the improved pharmacokinetics and tissue distribution, the decreased drug resistance 
and toxicity against healthy cells, together with enhanced accumulation and retention within tumor 
cells, are the key advantages of nanoassembled Sq-GEM versus GEM as such. A comprehensive 
review on this topic was recently published [56]. 
In general, the squalenoylation of antitumoral and antiviral drugs was achieved starting from 1,1’,2-
tris-nor-squalene acid. This intermediate was obtained from squalene, following a general procedure 
that was developed many years ago: it is the sinthon for obtaining many inhibitors of oxidosqualene 
cyclase and squalene epoxidase [57,58]. By a multistep reaction, starting from squalene treated with 




aldehyde, 1,1’,2-tris-nor-squalene acid was finally obtained by oxidation. Sq-GEM was obtained by 
reacting GEM with 1,1’,2-tris-nor-squalene acid, previously activated with ethylchloroformate 
(Figure 4) [52,53].  
Sq-GEM was also studied in regard to its interaction with biomembranes through DSC [59]. As 
synthetic biomembrane model, liposomal DMPC MLV were used. These studies entailed: 
1) DSC analysis of DMPC MLV containing increasing amounts of GEM, squalene, 1,1’,2-tris-
nor-squalene acid, or Sq-GEM; 
2) transfer of these compounds through an aqueous medium; 
3) migration of these compounds from liposomes containing a known quantity of GEM or Sq-
GEM to empty liposomes.  
The results showed that neither GEM nor squalene alone interact with the biomembrane model used. 
Conversely, 1,1’,2-tris-nor-squalene acid and Sq-GEM interacted strongly with the biomembrane 
model. The interaction of Sq-GEM with a biomembrane model was also studied, through the LB 
technique: the molecular area/surface pressure isotherms of GEM/lipid, Sq-GEM/lipid, and pure 
compound monolayers, taken together with the calorimetric results, indicate that Sq-GEM interacts 
with the phospholipid monolayer with the squalene moiety in contact with the phospholipid chains, 
while the GEM moiety protrudes into the aqueous medium. 
1,1’,2-tris-nor-squalenoyl-citarabine (Sq-ARA-C) was synthesised and formulated as nanoparticles 
(Figure 4) [60]. The antitumor activity was studied on murine leukaemia cell lines (L1210, 
responsive to ARA-C, and L1210R, resistant), a human leukaemia cell line (K562) and a human 
breast tumor cell line (MCF-7). Sq-ARA-C reduced the IC50 value by 2.5 times, for the L1210R 
cells, and by 4 times, for the K562 and MCF-7 cells, versus ARA-C. The activity of Sq-ARA-C on 
the murine leukaemia model L1210R was also studied, and the results showed a marked reduction in 
disease development. The biodistribution study of tritiated Sq-ARA-C in DBA/2 mice after 1 h 
showed the nanoparticles to be mainly localized in the spleen, liver and lungs, and to a much lesser 
extent in other organs, whereas a large quantity was still in the blood. After 24 h, the quantity present 
in the blood was greatly reduced, with a higher concentration in the RES organs. Sq-ARA-C showed 
a plasma half-life about 6 times that of ARA-C. The interaction of ARA-C and Sq-ARA-C with 
liposomal biomembranes (MLV) studied by DSC confirmed the results: the new compound 
interacted with the liposome system in different ways, since ARA-C and squalene had no effect on 
the transition temperature (Tm), while both Sq-ARA-C and 1,1’,2-tris-nor-squalene acid caused a 
decrease in the Tm, destabilising the membrane by inserting compounds between the phospholipid 
molecules [61]. 
The squalenoylation technology was also extended to develop a new ester prodrug with antiviral 
activity, squalenoyl-acyclovir (Sq-ACV). The interaction of Sq-ACV with biomembrane models 
made of DMPC MLV was studied by means of DSC and LB techniques [62,63]. The DSC study 
concerned the effects of ACV and of Sq-ACV towards the liposomal biomembranes (MLV) [62]. 
DSC was also run for squalene and 1,1’,2-tris-nor-squalene acid. ACV and squalene had no effect on 
the Tm, while both Sq-ACV and 1,1’,2-tris-nor-squalene acid produced a decrease in the Tm, 
causing destabilisation of the membrane, due to insertion of the compounds between the 
phospholipids; this shows that Sq-ACV is easily distributed in the phospholipid bilayers. In 
additional research, Sq-ACV nanoassemblies were obtained and the pharmacokinetics after ocular 
administration in rabbits was studied [64]. The lipophilic character of Sq-ACV optimizes permeation 
through the cornea, while the squalenoylation nanotechnology provides prolonged release of ACV at 
the absorption site. The ocular administration of Sq-ACV increased the bioavailability of ACV in 
both the tear fluid and the aqueous humor, to as much as four and six times the reference values, 
respectively. The intact prodrug was found in the lachrymal fluid, while it was not detected in the 
aqueous humor, thus ruling out passive transcorneal diffusion of the conjugate. The lipophilic 
character of Sq-ACV, associated with its high affinity for the ocular structure, might thus improve 




In the field of the squalenoylation of anticancer drugs, the most interesting results to date have been 
those achieved with DOX. The squalenoylation approach involved the synthesis of several 
derivatives having different characteristics: DOX-squalenoyl hydrazone (DOX-Hz-Sq), DOX-
squalenoyl ester hydrochloride (DOX-E-Sq) and DOX-squalenoyl amide (DOX-A-Sq). DOX-Hz-Sq 
contains an acid-sensitive hydrazone linker that allows DOX to be released either extracellularly, in 
the slightly acidic environment often present in tumor tissue, or intracellularly, in acidic endosomal 
or lysosomal compartments after cellular uptake by the tumor cell, as reported for DOX [65]. DOX-
E-Sq can also release the free drug under ester hydrolysis, while DOX-A-Sq appears to be very 
stable in in vitro studies. The synthesis of Sq-DOX derivatives is depicted in Figure 5. All DOX 
derivatives, with increasing hydrophobicity from DOX-E-Sq to DOX-A-Sq, were nanoprecipitated 
by simple solvent displacement in nanoassemblies of mean size 130-200 nm. It is significant that 
drug loading was impressively high (i.e. 57%). Preliminary in vitro data revealed DOX-E-Sq as the 
most promising compound of the series: in vivo toxicity studies, after intravenous administration, 
showed that the MTD of DOX-E-Sq nanoassemblies was up to five-fold that of the free drug and, 
more importantly, the squalene derivative did not cause any myocardial lesions, such as those 
observed after DOX treatment [66]. Concerning pharmacological activity, DOX-E-Sq 
nanoassemblies showed higher antitumor efficacy on both human pancreatic carcinoma and mouse 
lung tumor xenografts, compared to free DOX. Remarkably, tumor growth inhibition was marked 
also in DOX-resistant mouse lung tumor. Furthermore, DOX-E-Sq nanoassemblies also displayed 
lower toxicity and enhanced anticancer activity compared to the DOX liposomal formulations 
currently on the market [66]. 
The capacity of squalene-derived chains to form nanoassemblies when linked with hydrophilic drugs 
was thought to be due to the amphiphilic character of the bioconjugate: the squalene-derived part 
providing the lipophilic moiety, and the drug the hydrophilic part of the molecule. It was thus 
expected that this approach could only be applied to hydrophilic compounds. Unexpectedly, two 
studies showed that the squalenoylation technique may also be appropriate to design nanomedicines 
loaded with hydrophobic compounds having very low water solubility, like paclitaxel (PTX) [67], 
podophyllotoxin, camptothecin and epothilone [68]. It thus appeared that squalenoylation might also 
be a relevant technology for poorly water soluble compounds, which are difficult to administer 
intravenously. This approach was further developed in Prof. P. Couvreur’s laboratories, by 
modulating the linker between PTX and the squalene-derived chain [69]. 
The new technology has been extended to other therapeutic areas, such as antibiotics, for example 
penicillin G, using either a pH-sensitive or a pH-insensitive linker [70]. Formation of nanoassemblies 
was confirmed, and a significant proportion of S. aureus-infected macrophage cell lines were rapidly 
killed [71]. Application of the squalenoylation approach was also extended to statins (e.g. 
pravastatin), obtaining novel nanoassemblies with improved performance [72], and to antidiabetic 
agents, such as insulin [73]. Choosing different reactive conditions, several populations of 
squalenoylated insulin (one terminal amino term and two lysines) were fully identified and separated. 
Squalenoyl-insulin nanoassemblies were easily obtained by dialysis. The relevant patent also 
describes the preparation of derivatives and related nanoassemblies of 15-deoxyspergualine 
(Gusperimus), a hydrophilic drug useful in hyperactive inflammatory diseases, such as autoimmune 
diseases [74], that has also been used in an experimental approach to cystic fibrosis [75]. Other fields 
of application of squalenoylation are the topical delivery of vitamin C [76] as a potential anti-aging 
cosmetic. 
The squalenoylation platform was further employed for diagnostic agents. The contrast agent 
gadolinium Gd (III+) coupled to a squalene-derived chain was also synthesised, and preliminary in 
vivo data examined [77]. In our laboratory, a novel luminescent ruthenium (II) complex was linked 
to a squalene-derived chain. The resulting nanoassemblies exhibit long-lived and intense 
luminescence, and are rapidly transported across cell membrane. This cell-imaging tool was further 




diagnostic agents in the same structure is a powerful approach for nanomedicine delivery systems. 
Using the squalene-based platform, the combination by one-step nanoprecipitation of a squalenoyl 
bioconjugate solution containing magnetite nanocrystals (USPIO) was also achieved [79];it can be 
guided by an external magnetic field towards the tumor tissue, where it can be tracked by magnetic 
resonance imaging. This nanotechnology approach offers drug delivery combining diagnostic and 
therapeutic activities. For this purpose, various squalene-drug derivatives were tested (Sq-E-DOX, 
Sq-cisplatin, Sq-GEM) and formulated by one-step nanoprecipitation with USPIO. The USPIO/Sq–
GEM nanocomposites, injected in mice bearing the L1210 wt subcutaneous tumor model, was 
successfully guided by an external magnetic field towards the tumor tissue and tracked by magnetic 
resonance imaging.  
The most recent approach in squalenoylation nanotechnology is active targeting of squalene-derived 
nanoparticles. One strategy involves the co-nanoprecipitation of Sq-GEM with a squalene derivative 
of the CKAAKN peptide, which had been identified by phage display as an efficient homing device 
within the pancreatic pathological microenvironment. In vivo tests in RIP-Tag2 mice have showed 
that the CKAAKN functionalization enabled actively-targeted Sq-GEM nanoparticles: (i) to 
specifically interact with both tumor cells and angiogenic vessels, and (ii) to simultaneously promote 
pericyte coverage, thus leading to normalization of the vasculature, and likely improving tumor 
accessibility for therapy [80]. 
 
5) Mesoporous silica nanoparticles as a drug delivery system for topical applications 
Due to its siting, the skin is exposed to a large number of environmental threats; these include free 
radicals, which are implicated in a number of diseases and disorders. Antioxidants and free radical 
scavengers have thus been proposed as protective or therapeutic agents against these injuries. Oral 
treatment with antioxidants has been reported to provide skin protection against the deleterious 
effects of UV radiation and other oxidative stresses. Topical delivery of antioxidants has increasingly 
attracted interest, and recent developments include improved targeting to the upper skin layer. 
However, the cutaneous application of antioxidants is challenging, since this type of molecule is, in 
general, susceptible to degradation. The search for delivery systems that simultaneously preserve the 
stability of the active ingredient, and enhance skin deposition, constitute a new research field in drug 
delivery design [81].  
Over several decades, the Turin Research Group has devoted much effort to identifying new vehicles 
meeting these two goals, in both the dermatological and the cosmetic fields. The formulations 
studied include microemulsions [82], multiple emulsions [83], and vesicular systems (like 
liposomes) [84]. However, the advent of new functional substances, and the expectations of users, 
have lead to the introduction of more complex vehicles, which not only stabilize and release the 
active molecule at the target site, but also give the preparation an acceptable and pleasant feel, thus 
combining efficacy and aesthetics. Examples of this approach involve solid lipid nanoparticles 
[85,86], nanosponges [87], cyclodextrins [88-90], and more recently mesoporous silica nanoparticles 
[91]. 
Ordered mesoporous silica is a new development in nanotechnology: this material is now being 
produced on an industrial scale in a growing number of commercial products, its fabrication being 
simple, cost-effective, and controllable. The first mesoporous material was introduced in 1992 at 
Mobil Corporation laboratories and named Mobil Crystalline Materials (MCM-41), but it was not 
investigated in biomedical studies until 2001, when it was demonstrated to act as a drug delivery 
system [92]. Two research groups [93,94] proposed synthesis methods for mesoporous silica, 
reporting particles small enough to be considered for use as carrier for active compounds. Since these 
initial reports, extensive studies have been performed involving improved matrix synthesis, 
introduction of multifunctionality, and in vitro/in vivo experiments. The considerable interest in 
applying MCM-41 as a drug delivery system arises from a series of unique features: high surface 




uniform porous structure, thermal stability, water insolubility, and a silanol-containing surface that 
can easily be functionalized. Moreover, it has notable in vivo biocompatibility and biodegradability 
[95,96] and its porous interiors can be used as reservoirs for loading both hydrophilic and 
hydrophobic substances [92,97,98]. In addition, MCM-41 is reported to be able to increase the 
stability of included molecules and improve their bioavailability [99].  
The procedure for producing MCM-41 is simple, and the parameters can easily be controlled; the 
typical synthesis mixture contains four major components: inorganic precursors, organic template 
molecules, a solvent, and an acid or base catalyst [96,100]. The ordered mesoporous material is 
obtained by a supramolecular assembly of silica around surfactant micelles. The formation of the 
resulting material occurs by means of a “templating” mechanism in which the silicates form walls of 
inorganic material around the ordered micelles of surfactant. 
The immobilization of active molecules in this inorganic matrix for topical delivery has been 
reported. Particularly, in a recent paper [101], in order to reduce the sunscreen release from the 
formulation and to prevent contact between the UV absorbent and the skin, MCM-41 was proposed 
as a carrier for sunscreens; thus oxybenzone was included in its nanopores. The same group 
suggested MCM-41 as a matrix to host octylmethoxycinnamate, a well-known UV chemical filter: 
they reported a broader photoprotection range, enhanced photostability and reduced release of the 
included sunscreen [102].  
Another potential advantage of using MCM-41 as a topical carrier is its water sorbent property, 
which is due to the abundant presence of free silanol groups on its surface structure. Therefore, by 
forming hydrogen bonds, a large number of water molecules can be adsorbed; this can contribute to 
reducing the moisture present in the skin, responsible for maceration and the growth of 
microorganisms [103].  
In the light of these interesting developments, we studied the potential of MCM-41 as a carrier for 
Trolox® [104] and rutin [105], two hydrophilic derivatives of natural antioxidants, vitamin E and 
quercetin (Figure 6). The complexes between Trolox® and MCM-41 nanoparticles were prepared by 
employing different inclusion procedures, varying solvent and pretreatment of the silica matrix. The 
objectives of this study were to determine Trolox® loading, analyze its integrity and availability after 
immobilization on mesoporous silica, evaluate the influence of MCM-41 on its photostability, and 
establish whether the preparation method significantly influences complex properties. The physico-
chemical characterization, carried out by several techniques (X-ray diffraction, thermogravimetric 
analysis, DSC, and infrared spectroscopy), confirmed the host-guest interaction and Trolox® 
structure preservation. Gas-volumetric (BET) analysis showed a marked decrease in surface area and 
pore volume with respect to bare MCM-41, indicating that the antioxidant was present in the 
mesopores, and not simply located on the external surface. In vitro diffusion tests showed a slower 
release of Trolox® after immobilization in the inorganic matrix; at the same time, UV irradiation 
studies revealed increased photostability of the complex, particularly when dispersed in an emulsion 
system. Moreover, the radical scavenging activity of this hydrophilic derivative was maintained even 
after immobilization.  
For rutin, a complex was prepared using aminopropyl functionalized nanoparticles (NH2-MCM-41) 
to improve interaction with the guest molecule; the formulation was compared to that obtained with 
the parent MCM-41. Physico-chemical characterization, particularly BET analysis, evidenced the 
high rate of inclusion of rutin in the pores of NH2-MCM-41. Infrared spectroscopy demonstrated the 
formation of hydrogen-bonded adducts in both silica matrices, irrespective of surface 
functionalization, but in the case of functionalized silica, spectroscopy suggested that the 
aminopropyl groups play an important role in interaction with the quercetin aglycone, while on bare 
silica the interaction takes place through the rutinoside disaccharide. When exposed to UV 
illumination, mesoporous silica significantly improved rutin’s stability over time. Significantly, the 
protection appears to be correlated with both the presence of aminopropyl groups and the nature of 




rutin was demonstrated by both 2,2-diphenyl-1-picrylhydrazyl free radical (DPPH•) assay and the 
ferrous ion chelating test. Ex vivo experiments on Franz diffusion cells demonstrated that 
complexation with NH2-MCM-41 enhanced accumulation in the upper layer of the pigskin model.  
Considering these findings, MCM-41 may rationally be proposed as an innovative carrier for the 
topical delivery of unstable active molecules, although further investigation into MCM-41/skin 
surface interactions is necessary to assess the potential of this vehicle. 
 
6) Nanobubbles as carriers of hydrophilic molecules 
Recently, microbubbles and nanobubbles, spherical gas-filled core-shell structures, have gained 
increasing attention for drug and gene delivery. Their shell can be composed mainly of lipids or 
polymers, whereas the core can be filled with various gases, such as perfluorocarbons, sulphur 
hexafluoride, air, or carbon dioxide [106,107]. Nanobubbles have mean diameter in the nanometer 
order of magnitude, while microbubbles have mean diameter in the 1-6 micrometers range. The latter 
are currently on the market as contrast agents for ultrasound (US) imaging, because they undergo 
volumetric oscillations or acoustic cavitation when insonified by US and, particularly, they resonate 
at diagnostic frequencies [108,109]. More recently, nano-scaled bubbles have shown promising 
results for application as innovative nanocarriers, with improved stability and drug loading compared 
to microbubbles, as well as possessing extravasation capability. Thanks to their small size, 
extravasation from the blood vessels into the surrounding tissues is possible. Moreover, they might 
accumulate within tumor tissues via either the EPR effect [1,2] or through active targeting, i.e. by 
binding antibodies onto the bubble surface [110]. Ultrasound-triggered site-specific release of the 
incorporated drug, with minimal invasiveness, can then be achieved. Moreover, nanobubbles can act 
as a US-mediated nanocargo for the intracellular uptake of drugs [111]. All these features have been 
exploited for developing targeted delivery systems combined with ultrasonography. In addition, it is 
of note that a bubble-targeted strategy could make it possible to visualize the delivery and release of 
the loaded compound, through real-time echography imaging. 
Nanobubbles are mainly prepared by sonication, high shear emulsification, coacervation or 
coalescence; these techniques are also used in microbubble preparation [112]. 
Nanobubbles can be loaded with either hydrophilic or lipophilic molecules, and different 
technological approaches have been proposed to associate molecules within the bubble structure 
[113]. Drugs might be electrostatically bound to the bubble surface, or might otherwise be 
incorporated within or just beneath the nanobubble shell. Alternatively, they can be previously 
loaded into a nanosystem, which can then be linked to the nanobubble surface.  
Considering hydrophilic drugs, a number of purpose-built formulations have been designed. 
Particularly, hydrophilic molecules can be directly attached to the outer nanobubble surface, 
exploiting electrostatic interactions; they can also be included in the nanobubble inner core using 
technological approaches. 
The US-mediated therapeutic strategy associated with hydrophilic drugs was firstly proposed for 
cancer chemotherapy [114,115], but this nanotechnology showed potential for other applications. A 
polymeric nanobubble system has been produced to increase the sensitivity of cancer cells to Cox 
associated to US [116]. The developed systems comprise perfluorocarbon nanodroplets stabilized by 
a biodegradable block copolymer wall. Upon heating to physiological temperatures, the nanodroplets 
convert into nano/microbubbles. Under the action of tumor-directed ultrasound, microbubbles 
cavitate and collapse, releasing the encapsulated drug. Due to the ultrasound-enhanced intracellular 
drug uptake, DOX-loaded nanobubbles proved effective in in vivo tumor chemotherapy.  
More recently, nanobubbles have been developed by encapsulating DOX-HCl into poly(lactic-co-
glycolic acid) (PLGA) shells for drug delivery into cancer cells; pH-triggered release profile of DOX 
from nanobubbles was achieved. DOX-loaded nanobubbles were internalized in HeLa cells in both a 
concentration- and a time-dependent manner, and has a stronger cell-growth inhibition effect in vitro 




Nanobubbles have also been developed with the aim of obtaining more efficient gene delivery 
systems [118]. For this purpose, bubble liposomes have been produced with sizes between 150-200 
nm. After injection into mice, they successfully showed that gene uptake was limited to the area 
exposed to US, indicating that the system could be used to increase DNA transduction [119]. In the 
context of gene delivery, US-sensitive nanobubbles bearing siRNA for tumor therapy have been 
synthesized by a hetero assembling strategy, in order to target the anti-apoptosis gene sirtuin 2. The 
application of US enhanced the gene silencing effect of siRNA-nanobubbles both in vitro and in 
vivo; this lead to a high rate of cancer cell apoptosis. Consequently, a significantly improved 
therapeutic effect was achieved in a nude mouse glioma model. The US-sensitive siRNA 
nanobubbles may be an ideal delivery vector to mediate highly effective RNA interference for tumor 
treatment [120]. 
Nanobubbles carrying androgen receptor (AR) siRNA have been prepared using poly-L-lysine and 
electrostatic adsorption methods. Treatment with siRNA-nanobubbles combined to ultrasonic 
irradiation significantly inhibited cell growth and resulted in the suppression of AR mRNA and 
protein expression. Based on these results, nanobubbles carrying AR siRNA might potentially be 
used as gene vectors in combination with ultrasonic irradiation for the treatment of androgen-
independent prostate cancer [121].  
Lipid-based nanobubbles containing perfluoropentane were prepared for the delivery of apomorphine 
hydrochloride, a chemically-unstable dopamine receptor agonist with low bioavailability. Its 
encapsulation within a delivery system might overcome these drawbacks. The in vitro drug release 
was sustained over time and it was enhanced by insonation, demonstrating a possible drug-targeting 
effect [122]. 
In work done by the Turin Group, polymer-shelled and perfluoropentane-cored nanobubbles were 
designed as versatile multifunctional carriers for the delivery of gases, drugs and genes (Figure 7). 
These nanobubbles were of size below 500 nm, with shell thickness in the 30-50 nm range. For the 
nanobubble core, perfluoropentane was chosen, because it is a perfluorocarbon that is liquid at room 
temperature (boiling point 29 °C); it converts into vapor in the presence of US, through a mechanism 
known as acoustic droplet vaporization [123]. Consequently, it is possible to prepare stable 
perfluoropentane nanoemulsions with a simple preparation set-up (compared with the use of gases), 
which then convert into bubbles after the liquid-to-gas transition. These perfluoropentane-cored 
nanobubbles were found to be echogenic and stable without morphological changes or shrinkage, 
after insonation for 5 minutes at 2.5 MHz. They did not affect the viability of several different cell 
lines. Confocal microscopy showed the nanobubble capacity to be internalized in cells. 
Based on the premise that large amounts of oxygen can be dissolved in perfluoropentane, oxygen-
filled nanobubbles were obtained using either chitosan or dextran for the shell [124,125]. They were 
able to store oxygen and then slowly release it in hypoxic environments, after exposure to US [126]. 
To increase the oxygen loading, alternative US-responsive nanodroplets, consisting of 
decafluoropentane and chitosan, were developed and formulated in a hydrogel preparation, to treat 
hypoxic diseases of the dermal and subcutaneous tissues [127]. 
A peculiar perfluoropentane-cored nanobubble formulation, comprising a diethylaminoethyl-dextran 
(DEAE)-based shell with positive surface charge, was designed to complex DNA. DEAE 
nanobubbles were able to protect their cargo from the action of proteases, and to transfect plasmid 
DNA without any resulting cytotoxic effects [128]. Subsequently, chitosan-based shelled 
formulations were proposed for DNA delivery [129]. Chitosan was selected for the nanobubble shell 
because it is a polycationic polymer with low toxicity, low immunogenicity, and excellent 
biocompatibility. DNA-loaded chitosan nanobubbles were formed with mean diameter below 300 
nm and positive surface charge. In vitro transfection experiments were performed on COS7 cells. In 
the absence of US, nanobubbles failed to trigger transfection at any of the concentrations tested; in 
contrast, 30 seconds of US (2.5 MHz) promoted a moderate degree of transfection without affecting 




In addition, dextran-shelled nanobubbles were also exploited to deliver vancomycin, a hydrophilic 
antibiotic used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. 
This drug has low oral bioavailability and its systemic administration can cause severe adverse 
effects. These drawbacks could be overcome by the topical administration of vancomycin loaded in 
nanobubbles. Vancomycin-loaded nanobubbles were about 300 nm in size with a negative surface 
charge, an EE% of 86% and a loading capacity of 29%. In vitro studies demonstrated prolonged 
release kinetics and absence of toxicity on keratinocytes. The antibacterial activity against MRSA of 
vancomycin-loaded nanobubbles was confirmed in vitro. The application of US in combination with 
nanobubbles enhanced both in vitro release and drug permeation through a pigskin model. 
Vancomycin properly formulated in US-responsive nanobubbles might be a promising strategy for 
the topical treatment of MRSA infections [130]. 
 
Conclusion 
This review has discussed different DDS developed in Turin University. Although hydrophobic 
drugs also benefit from loading into nanostructures (e.g., increasing their aqueous solubility), the 
present article has mainly focused on strategies to improve the performance of hydrophilic drugs. 
The new DDS that have been developed possess improved properties compared to the free drug or 
parent substance, namely:  
● regulated drug release from the DDS, reducing healthy tissue damage; 
● protection of the encapsulated molecule from premature degradation, meaning lower doses are 
required; 
● different pharmacokinetics, often similar to that of the DDS, lowering the volume of 
distribution, and avoiding rapid clearance; 
● in the case of antitumor drugs, increased concentration in diseased tissues caused by the EPR 
effect, and in some cases by ligand-mediated targeting, further improving drug specificity. 
Some of these delivery systems are made of lipidic compounds: natural or synthetic phospholipids 
for liposomes, fatty acids for SLN, or squalene-derived chains for squalenoyl nanoparticles. Other 
systems are mainly composed of natural or synthetic polymers, such as drug-loaded nanobubbles, or 
totally synthetic polymers, such as polyalkylcyanoacrylate carriers, both nanospheres and 
nanocapsules. Inorganic materials, such as mesoporous silica particles, are receiving increasing 
attention as modern drug delivery systems essentially for their high biocompatibility and 
considerable versatility. 
To conclude, this review has described the wide range of new drug delivery technologies developed 
by the Turin research group to encapsulate hydrophilic molecules, also examing some issues 
concerning physical, chemical, technological, pharmacological, and biological aspects of the DDS.  
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Figure 4. Synthesis of 4-(N)-squalenoyl-gemcitabine (Sq-GEM) (3) and of 1,1’,2-tris-nor-
































Figure 7. Schematic representation of polymer-shelled nanobubble structure and different loading 
strategies. 
 
